MX2017006812A - Composición farmacéutica, preparación y usos de la misma. - Google Patents

Composición farmacéutica, preparación y usos de la misma.

Info

Publication number
MX2017006812A
MX2017006812A MX2017006812A MX2017006812A MX2017006812A MX 2017006812 A MX2017006812 A MX 2017006812A MX 2017006812 A MX2017006812 A MX 2017006812A MX 2017006812 A MX2017006812 A MX 2017006812A MX 2017006812 A MX2017006812 A MX 2017006812A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compound
carrier
biocompatible nanoparticle
subject
need
Prior art date
Application number
MX2017006812A
Other languages
English (en)
Inventor
Levy Laurent
Meyre Marie-Edith
Pottier Agnès
Germain Matthieu
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of MX2017006812A publication Critical patent/MX2017006812A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con una composición farmacéutica que comprende una combinación de al menos una nanopartícula biocompatible y de al menos un portador integrado de al menos un compuesto farmacéutico a ser administrado a un sujeto necesitado de dicho compuesto farmacéutico, donde la combinación de al menos una nanopartícula biocompatible y al menos un portador integrado de un compuesto farmacéutico potencializa la eficiencia de interés del compuesto. La dimensión más larga de la nanopartícula biocompatible está típicamente entre 4 y 500 Nm y su valor absoluto de carga de la superficie es de al menos 10Mv (10 m V). El portador, adicionalmente, carece de cualquier agente de superficie estéricamente estabilizada. La invención también se relaciona a dicha composición para uso en la administración de compuesto(s) del mismo, donde al menos una nanopartícula biocompatible y al menos un portador integrado de al menos un compuesto farmacéutico serán administrados separadamente a un sujeto necesitado de dicho compuesto farmacéutico, típicamente entre más de 5 minutos y 72 horas uno de otro.
MX2017006812A 2014-11-25 2015-11-24 Composición farmacéutica, preparación y usos de la misma. MX2017006812A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14306875 2014-11-25
PCT/EP2015/077425 WO2016083333A1 (en) 2014-11-25 2015-11-24 Pharmaceutical composition, preparation and uses thereof

Publications (1)

Publication Number Publication Date
MX2017006812A true MX2017006812A (es) 2018-02-12

Family

ID=52013982

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017006812A MX2017006812A (es) 2014-11-25 2015-11-24 Composición farmacéutica, preparación y usos de la misma.
MX2021010595A MX2021010595A (es) 2014-11-25 2017-05-24 Composicion farmaceutica, preparacion y usos de la misma.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021010595A MX2021010595A (es) 2014-11-25 2017-05-24 Composicion farmaceutica, preparacion y usos de la misma.

Country Status (22)

Country Link
US (1) US10765632B2 (es)
EP (2) EP3236934B1 (es)
JP (1) JP6789960B2 (es)
KR (1) KR102666251B1 (es)
CN (1) CN107106703A (es)
AR (1) AR102782A1 (es)
AU (1) AU2015352685B2 (es)
BR (1) BR112017010953B1 (es)
CA (1) CA2968919C (es)
DK (1) DK3236934T3 (es)
EA (1) EA201791147A1 (es)
FI (1) FI3236934T3 (es)
HK (1) HK1245085A1 (es)
IL (2) IL252462B (es)
LT (1) LT3236934T (es)
MX (2) MX2017006812A (es)
NZ (1) NZ769187A (es)
PT (1) PT3236934T (es)
SG (1) SG11201704219UA (es)
TW (1) TW201628656A (es)
UA (1) UA123665C2 (es)
WO (1) WO2016083333A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105407878A (zh) 2013-05-30 2016-03-16 纳米生物技术公司 药物组合物、制备及其用途
US11304902B2 (en) 2014-11-25 2022-04-19 Curadigm Sas Pharmaceutical compositions, preparation and uses thereof
US20170258937A1 (en) 2014-11-25 2017-09-14 Nanobiotix Pharmaceutical composition, preparation and uses thereof
EP3229776B1 (en) 2014-11-25 2023-06-28 Curadigm Sas Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof
WO2016189125A1 (en) 2015-05-28 2016-12-01 Nanobiotix Nanoparticles for use as a therapeutic vaccine

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
JPH10120597A (ja) 1996-10-22 1998-05-12 Eiken Chem Co Ltd リンパ節高集積性コロイド粒子
CA2511464C (en) * 2002-12-31 2011-08-23 Bharat Serums & Vaccines Ltd. Non-pegylated long-circulating liposomes
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
JP5513708B2 (ja) * 2003-12-22 2014-06-04 ブラッコ・シュイス・ソシエテ・アノニム 造影イメージング用の気体封入マイクロベシクル・アセンブリー
US20080193372A1 (en) * 2004-02-10 2008-08-14 Barnes-Jewish Hospital Efficacy and Safety of Targeted Particulate Agents with Decoy Systems
US20060264804A1 (en) * 2005-04-07 2006-11-23 Yoram Karmon Device and kit for delivery of encapsulated substances and methods of use thereof
US20070088414A1 (en) * 2005-05-25 2007-04-19 Campbell Robert L Particulate formulations for intradermal delivery of biologically active agents
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
WO2007122956A1 (ja) * 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
WO2007116954A2 (en) 2006-03-30 2007-10-18 Fujifilm Corporation Inorganic nanoparticle comprising an active substance immobilized on the surface and a polymer
AU2007247770B2 (en) 2006-05-04 2013-07-18 Reformpharm Pty Ltd Drug release from nanoparticle-coated capsules
JP2010536874A (ja) * 2007-08-21 2010-12-02 アルザ・コーポレーシヨン ボロン酸化合物をインビボ投与するためのリポソーム組成物
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
US20100272639A1 (en) 2007-12-21 2010-10-28 John Robert Dutcher Polysaccharide nanoparticles
EP2280601A4 (en) 2008-02-21 2012-08-29 Sequoia Pharmaceuticals Inc AMINO ACID HEMMER OF CYTOCHROM P450
WO2009142754A1 (en) 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
EP2130553A1 (en) 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
WO2010048623A2 (en) 2008-10-26 2010-04-29 Board Of Regents, The University Of Texas Systems Medical and imaging nanoclusters
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
CN102781472B (zh) 2010-02-17 2014-07-02 国立大学法人神户大学 放射线治疗剂
MX346861B (es) 2010-03-26 2017-04-04 Abraxis Bioscience Llc * Metodos de tratamiento de carcinoma hepato celular.
GB201009455D0 (en) 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
JP5713311B2 (ja) * 2010-09-24 2015-05-07 国立大学法人名古屋大学 リポソーム複合体、その製造方法、及びその使用
WO2012051220A1 (en) 2010-10-11 2012-04-19 Wichita State University Composite magnetic nanoparticle drug delivery system
US20140227343A1 (en) * 2011-01-31 2014-08-14 Centre National De La Recherche Scientifique Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles
US9956175B2 (en) 2011-01-31 2018-05-01 Nanobiotix Nanoparticles delivery systems, preparation and uses thereof
US10251841B2 (en) 2011-10-17 2019-04-09 Trustees Of Boston University Polymeric depots for localization of agent to biological sites
US20150209397A1 (en) 2012-09-07 2015-07-30 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
ITRM20120480A1 (it) * 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
CN105407878A (zh) 2013-05-30 2016-03-16 纳米生物技术公司 药物组合物、制备及其用途
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
AR102779A1 (es) 2014-11-25 2017-03-22 Nanobiotix Composición farmacéutica, su preparación y sus usos
US20170258937A1 (en) 2014-11-25 2017-09-14 Nanobiotix Pharmaceutical composition, preparation and uses thereof
EP3229776B1 (en) * 2014-11-25 2023-06-28 Curadigm Sas Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof
US11304902B2 (en) 2014-11-25 2022-04-19 Curadigm Sas Pharmaceutical compositions, preparation and uses thereof

Also Published As

Publication number Publication date
UA123665C2 (uk) 2021-05-12
LT3236934T (lt) 2024-08-26
FI3236934T3 (fi) 2024-07-22
PT3236934T (pt) 2024-08-01
AU2015352685B2 (en) 2020-09-17
AU2015352685A1 (en) 2017-07-13
CN107106703A (zh) 2017-08-29
IL290114A (en) 2022-03-01
CA2968919A1 (en) 2016-06-02
IL252462B (en) 2022-03-01
AR102782A1 (es) 2017-03-22
BR112017010953B1 (pt) 2024-01-16
MX2021010595A (es) 2021-09-23
US10765632B2 (en) 2020-09-08
HK1245085A1 (zh) 2018-08-24
US20170258721A1 (en) 2017-09-14
TW201628656A (zh) 2016-08-16
IL252462A0 (en) 2017-07-31
NZ769187A (en) 2023-07-28
JP6789960B2 (ja) 2020-11-25
SG11201704219UA (en) 2017-06-29
NZ732995A (en) 2021-01-29
BR112017010953A2 (pt) 2018-02-14
EP3236934A1 (en) 2017-11-01
EP3236934B1 (en) 2024-05-22
EP4431155A2 (en) 2024-09-18
KR102666251B1 (ko) 2024-05-27
CA2968919C (en) 2023-07-18
EA201791147A1 (ru) 2017-11-30
DK3236934T3 (da) 2024-08-19
KR20170093860A (ko) 2017-08-16
WO2016083333A1 (en) 2016-06-02
JP2017538783A (ja) 2017-12-28

Similar Documents

Publication Publication Date Title
NZ714273A (en) Pharmaceutical composition comprising the combination of a biocompatible nanoparticle and a compound of interest, preparation and uses thereof
MX2021010595A (es) Composicion farmaceutica, preparacion y usos de la misma.
MX2017006813A (es) Composicion farmaceutica, preparacion y usos de la misma.
WO2017042607A3 (en) Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain
MY196319A (en) Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
MX2019015578A (es) Metodos para tratar la enfermedad de huntington.
MX2017012131A (es) Composiciones y métodos para la administración de agentes de biomacromoléculas.
MX355330B (es) Formas cristalinas de compuestos terapeuticos y sus usos.
MX2019007187A (es) Composiciones para el cuidado bucal.
WO2014113429A3 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
EP4360712A3 (en) Aryl- or heteroaryl-substituted benzene compounds
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
WO2015104292A3 (en) Compounds for use in treating or preventing cancerous diseases
WO2015023691A3 (en) 4-methylumbelliferone treatment for immune modulation
PH12016501519B1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
SG10201907291QA (en) Monomethylfumarate prodrug compositions
MY179605A (en) Use of benzimidazole-proline derivatives
MX342947B (es) Tratamiento de diabetes tipo 2.
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
MX2017016231A (es) Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina.
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
MX2019007361A (es) Composiciones para el cuidado bucal.
BR112015014092A2 (pt) administração oral transmucosal de acetato de glatirâmer
MX2015011588A (es) Tratamiento de combinacion.
IN2013MU01177A (es)